[{"id":"e21d1243-ddfa-45d3-a98f-caab0653a167","acronym":"","url":"https://clinicaltrials.gov/study/NCT04381650","created_at":"2021-01-18T21:09:35.128Z","updated_at":"2024-07-02T16:35:13.306Z","phase":"Phase 1/2","brief_title":"A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04381650","lead_sponsor":"Takeda","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK rearrangement • ALK fusion","tags":["EGFR • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK rearrangement • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • subasumstat (TAK-981)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/17/2020","start_date":" 08/17/2020","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-22"},{"id":"d45ba617-287d-4d20-b7f9-60232b733564","acronym":"","url":"https://clinicaltrials.gov/study/NCT04065555","created_at":"2021-02-12T16:54:14.811Z","updated_at":"2025-02-25T14:51:31.104Z","phase":"Phase 1","brief_title":"Intratumoral Microdosing of TAK-981 in Head and Neck Cancer","source_id_and_acronym":"NCT04065555","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Bavencio (avelumab) • subasumstat (TAK-981)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 06/20/2022","primary_completion_date":" 06/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2022-07-29"}]